国家药品集中采购政策对ARB类药物使用的影响  

Effects of National Centralized Drug Procurement on the Use of ARB Drugs

作　　者：赵成龙[1] 张冬燕[1] 闫静静[1] 任远[1] 马培志[1] ZHAO Chenglong;ZHANG Dongyan;YAN Jingjing;REN Yuan;MA Peizhi(Department of Pharmacy,Henan Provincial People’s Hospital,Zhengzhou 450003,China)

机构地区：[1]河南省人民医院药学部,河南郑州450003

出　　处：《河南医学研究》2021年第13期2360-2363,共4页Henan Medical Research

摘　　要：目的分析国家药品集中采购政策对血管紧张素Ⅱ受体阻滞剂(ARB)类药物使用的影响,为医疗机构药事管理提供参考。方法对国家药品集中采购政策实施后的2020年5—10月和2019年同期门诊ARB类药物使用数量、金额和日均费用等指标进行分析。结果国家药品集中采购政策实施后,全院门诊ARB类药物整体使用片数同比增长5.66%,金额降低26.34%,为75万余元。纳入国家集中采购的5种通用名的药品使用片数同比降低1.13%,金额降低71.40%,为102万余元。5种中选药品2020年使用片数均占同通用名药品的75%以上,而未中选药品使用片数占比下降。结论国家药品集中采购政策切实降低了患者的用药负担。Objective To analyze the influence of national centralized drug procurement on the use of(angiotensinⅡreceptor blocker,ARB)drugs,and to provide reference for hospital drug management.Methods The sales number,sales amount and defined daily cost of ARB drugs used in outpatient department from May to October 2020 after implementation of the national centralized drug procurement and corresponding period in 2019 were analyzed.Results After the implementation of the national centralized drug procurement,the total number of ARB drugs used in outpatient department increased by 5.66%,but the amount decreased by 26.34%(more than 750000 yuan).The number of 5 generic drugs included in the national centralized drug procurement decreased by 1.13%,and the amount decreased by 71.40%(more than 1.02 million yuan).In 2020,the number of the 5 selected drugs accounted for more than 75%of the same generic drugs,while the proportion of unselected drugs decreased.Conclusion The national centralized drug procurement effectively reduce the drug burden of patients.

关 键 词：国家药品集中采购政策 高血压 血管紧张素Ⅱ受体阻滞剂 

分 类 号：R951[医药卫生—药学]